Type 2 diabetes therapy

References

• DeFronzo RA. Lilly lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37(6): 667–87
   Google Scholar
• Warram JH, Martin BC, Krowlewski AS, et al. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic patients. Ann Intern Med 1990; 113(12): 909–15
   PubMed Web of Science ®Google Scholar
• Shulman Gl, Rothman DL, Jue T, et al. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 1990,322(4): 223–8
   Google Scholar
• Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989; 321(6): 337–43
   PubMed Web of Science ®Google Scholar
• Nesher R, Della Casa L, Litvin Y, et al. Insulin deficiency and insulin resistance in type 2 (non-insulin-dependent) diabetes: quantitative contributions of pancreatic and peripheral responses to glucose homeostasis. Eur J Clin Invest 1987; 17(3): 266–74
   Google Scholar
• Roder ME, Dinesen B, Hartling SG, et al. Intact proinsulin and β-cell function in lean and obese subjects with and without type 2 diabetes. Diabetes Care 1999; 22(4):609–14
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989; 38(4): 387–95
   PubMed Web of Science ®Google Scholar
• Standards of medical care for patients with diabetes mellitus. American Diabetes Association. Diabetes Care 2001; 24(Suppl 1): S33–43
   Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977–86
   PubMed Web of Science ®Google Scholar
• Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23(Suppl 2): B21–9
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Matthews DR, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258): 405–12
   PubMed Web of Science ®Google Scholar
• Simonson DC, Ferrannini E, Bevilacqua S, et al. Mechanism of improvement in glucose metabolism after chronic glyburide therapy. Diabetes 1984; 33(9):838–45
   Google Scholar
• Leibowitz G, Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing? Diabetologia 1996; 39(5): 503–14
   PubMed Web of Science ®Google Scholar
• Kilo C, Miller JP, Williamson JR. The Achilles heel of the University Group Diabetes Program. JAMA 1980; 243(5): 450–7
   PubMed Web of Science ®Google Scholar
• Intensive Blood-Glucose Control With Sulphonylureas Or Insulin Compared With Conventional Treatment And Risk Of Complications In Patients With Type 2 Diabetes (Ukpds 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 837–53
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Samols E, Muchmore DB, et al. Glimepiride, a new once-daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 1996; 19(11): 1194–9
   Google Scholar
• Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281(21): 2005–12
   PubMed Web of Science ®Google Scholar
• Damsbo P, Clauson P, Marbury TC, et al. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 1999; 22(5): 789–94
   PubMed Web of Science ®Google Scholar
• Jovanovic L, Dailey G III, Huang WC, et al. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. J Clin Pharmacol 2000; 40(1): 49–57
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Bouter KP, Dickinson S, et al. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000; 23(2): 202–7
   PubMed Web of Science ®Google Scholar
• Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338(13): 867–72
   PubMed Web of Science ®Google Scholar
• Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49(12): 2063–9
   PubMed Web of Science ®Google Scholar
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131): 854–65
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333(9): 541–9
   PubMed Web of Science ®Google Scholar
• Balfour JA, McTavish D. Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46(6): 1025–54
   Google Scholar
• Coniff RF, Shapiro JA, Robbins D, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM: placebo-controlled dose-comparison study. Diabetes Care 1995; 18(6): 817–24
   PubMed Web of Science ®Google Scholar
• Yu JG, Kruszynska YT, Mulford MI, et al. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes 1999; 48(12): 2414–21
   Google Scholar
• Mathisen A, Geerlof J, Houser V. The effect of pioglitazone on glucose control and lipid profile in patients with type 2 diabetes. Diabetes 1999; 48(Suppl 1): A102–3
   Google Scholar
• Nolan JJ, Jones NP, Patwardhan R, et al. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabetic Med 2000; 17(4): 287–94
   Google Scholar
• Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001; 7(3): 162–9
   Google Scholar
• Tack CJ, Smits P, Demacker PN, et al. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care 1998; 21(5): 796–9
   PubMed Web of Science ®Google Scholar
• Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134(1):61–71
   PubMedGoogle Scholar